‘Unusual’ symptoms of mutant Covid strain: South African doctor who first raised alarm about Omicron warns its early signs are ‘MILD’ and patients do NOT lose their sense of smell

The South African doctor who first raised the alarm on new Covid variant Omicron has revealed that patients are presenting with ‘unusual’ symptoms.  

Dr Angelique Coetzee, who runs a private practice in the South African administrative capital of Pretoria, said she first noticed earlier this month that Covid patients were presenting with a host of odd symptoms. 

The doctor, who has practiced for over 30 years and chairs the South African Medical Association, said that none of the Omicron patients suffered from a loss of taste of smell typically associated with Covid, but instead presented with unusual markers like intense fatigue and a high pulse rate. 

‘Their symptoms were so different and so mild from those I had treated before,’ Dr Coetzee told The Telegraph. 

She was compelled to inform South Africa’s vaccine advisory board on November 18 when she treated a family of four, all of whom were suffering with intense fatigue after testing positive for Covid-19. 

First discovered in South Africa earlier this month, Omicron has since been detected in Britain, Germany, Italy, Belgium, Botswana, Israel, Hong Kong and Australia, while Austrian health authorities are today conducting an investigation into a suspected

The discovery of Omicron, dubbed a ‘variant of concern’ last week by the World Health Organisation (WHO), has sparked worries around the world that it could resist vaccinations and prolong the nearly two-year pandemic.

Omicron is potentially more contagious than previous variants, although experts do not yet know if it will cause more or less severe Covid-19 compared to other strains.

Dr Coetzee reassured the media that the new symptoms she had observed were ‘mild’, and that all of the patients she was treating had recovered well. 

‘We had one very interesting case, a kid, about six years old, with a temperature and a very high pulse rate, and I wondered if I should admit her,’ Dr Coetzee said,

‘When I followed up two days later, she was so much better.’

But the doctor also said she was worried the variant could pose a greater danger to the elderly.

The discovery of the new variant has prompted several countries to reinforce Covid restrictions and impose stringent border controls in an attempt to contain the spread. 

<
Omicron is potentially more contagious than previous variants, although experts do not yet know if it will cause more or less severe Covid-19 compared to other strains (a man undergoes a Covid test in Sydney International Airport this morning)

Prime Minister Boris Johnson yesterday imposed isolation for all UK arrivals pending PCR test results and mandatory masks in shops and on trains, and placed a host of countries on the ‘red list’ for travel restrictions.

Switzerland has said that only Swiss nationals and permanent residents can enter, but a pre-departure negative test must be proven alongside a 10-day mandatory quarantine, while Spain has also announced a ban on unvaccinated Britons after neighbour Portugal said it would demand proof of a negative coronavirus test to let even the double-jabbed enter the country. 

Health authorities in Australia’s New South Wales meanwhile will send people who have been overseas in the two weeks before their arrival into three days of home quarantine, after the state registered two cases of Omicron and closed borders to several Southern African countries.

Immunologist and member of the British Government’s vaccine task force Sir John Bell said on Friday that it was too late to stop ‘the monster’ variant from reaching our shores, and that it was a ‘matter of time’ before more Britons are infected.  

But Sir John also said that a ‘tweak’ to our existing coronavirus vaccines could prove effective in combatting the new variant should the existing ones prove ineffective, and that Britain is already well placed to make the switch quickly thanks to research being carried out by the Oxford/AstraZeneca team. 

Share

Leave a Reply

Your email address will not be published. Required fields are marked *